脂质代谢异常与慢性肾脏病合并心血管疾病的研究进展  

The research progress on abnormal lipid metabolism and chronic kidney disease with cardiovascular disease

作　　者：欧三桃 李艳 OU Santao;LI Yan(Department of Nephrology,the Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,China;Sichuan Clinical Research Center for Nephrology,Luzhou,Sichuan 646000,China)

机构地区：[1]西南医科大学附属医院肾病内科 [2]四川省肾脏病临床医学研究中心,四川省泸州市646000

出　　处：《中国动脉硬化杂志》2022年第8期654-660,共7页Chinese Journal of Arteriosclerosis

基　　金：四川省肾脏疾病临床医学研究中心2020年开放课题重点项目(2019YFS0537-3)。

摘　　要：慢性肾脏病(CKD)的患病率逐年上升,而心血管疾病(CVD)是导致其死亡的主要原因。CKD患者往往同时合并脂质代谢异常,这是促进CVD发生发展的重要因素,但CKD患者的脂质代谢异常与CVD发病率和死亡率之间的关系有其特殊性,各类降脂治疗能否有效改善CKD患者的CVD也存在争议。因此,文章就脂质代谢异常与CKD患者合并CVD发生的病理生理机制及相关性作一综述,这对降低CKD患者CVD发生率及改善患者预后具有十分重要的意义。The prevalence of chronic kidney disease(CKD)is increasing year by year,and cardiovascular disease(CVD)is the main cause of death.Patients with CKD are often complicated with abnormal lipid metabolism,which is a significant factor in promoting the occurrence and development of CVD.However,the relationship between dyslipidemia in CKD patients and morbidity and mortality of CVD has its particularity,and it is controversial whether various lipid-lowering treatments can effectively improve CVD in patients with CKD.Therefore,this article reviews the pathophysiological mechanism and correlation between abnormal lipid metabolism and CKD patients with CVD,which is of exceedingly significance to reduce the incidence of CVD and improve the prognosis of CKD.

关 键 词：脂质代谢异常 慢性肾脏病 心血管疾病 

分 类 号：R5[医药卫生—内科学]